دورية أكاديمية

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

التفاصيل البيبلوغرافية
العنوان: Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
المؤلفون: Nakamura, Ryota, Yamada, Tadaaki, Tokuda, Shinsaku, Morimoto, Kenji, Katayama, Yuki, Matsui, Yohei, Hirai, Soichi, Ishida, Masaki, Kawachi, Hayato, Sawada, Ryo, Tachibana, Yusuke, Osoegawa, Atsushi, Horinaka, Mano, Sakai, Toshiyuki, Yasuhiro, Tomoko, Kozaki, Ryohei, Yano, Seiji, Takayama, Koichi
المصدر: In Cancer Letters 28 August 2024 598
قاعدة البيانات: ScienceDirect
الوصف
تدمد:03043835
DOI:10.1016/j.canlet.2024.217124